Monotherapy with immune checkpoint inhibitors has shown limited clinical activity in patients with microsatellite stable (MSS) colorectal cancer (CRC). Here the authors report the results of a clinical trial of tislelizumab (anti-PD1) in combination with cetuximab (anti-EGFR) and irinotecan in patients with refractory MSS and RAS wild-type metastatic CRC.
- Xiaojing Xu
- Luoyan Ai
- Tianshu Liu
